Wedbush analysts pointed out that the preliminary DT-216 Phase 1 SAD data yielded a 2-fold increase in frataxin mRNA expression, but there were no change in protein expression. And the analysts believe that investor expectations were a bit stretched since only a single dose was administered as part of a SAD study that was a proof-of-mechanism experiment. The second MAD data will include muscle biopsies, but FXN protein expression changes will likely require longer-term DT-216 exposure.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.